Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Clin Oncol ; : JCO2400733, 2024 May 31.
Article in English | MEDLINE | ID: mdl-38843511

ABSTRACT

PURPOSE: The open-label, phase III EVOKE-01 study evaluated sacituzumab govitecan (SG) versus standard-of-care docetaxel in metastatic non-small cell lung cancer (mNSCLC) with progression on/after platinum-based chemotherapy, anti-PD-(L)1, and targeted treatment for actionable genomic alterations (AGAs). Primary analysis is reported. METHODS: Patients were randomly assigned 1:1 (stratified by histology, best response to last anti-PD-(L)1-containing regimen, and AGA treatment received or not) to SG (one 10 mg/kg intravenous infusion on days 1 and 8) or docetaxel (one 75 mg/m2 intravenous infusion on day 1) in 21-day cycles. Primary end point was overall survival (OS). Key secondary end points were investigator-assessed progression-free survival (PFS), objective response rate, patient-reported symptom assessment, and safety. RESULTS: In the intention-to-treat population (SG, n = 299; docetaxel, n = 304), 55.4% had one previous line of therapy. Median follow-up was 12.7 months (range, 6.0-24.0). The primary end point was not met. There was a numerical OS improvement for SG versus docetaxel (median, 11.1 v 9.8 months; hazard ratio [HR], 0.84 [95% CI, 0.68 to 1.04]; one-sided P = .0534), consistent across squamous and nonsquamous histologies. Median PFS was 4.1 versus 3.9 months (HR, 0.92 [95% CI, 0.77 to 1.11]). An OS benefit was observed for SG (n = 192) versus docetaxel (n = 191) in mNSCLC nonresponsive to last anti-PD-(L)1-containing regimen (3.5-month median OS increase; HR, 0.75 [95% CI, 0.58 to 0.97]); this was consistent across histologies. Among patients receiving SG and docetaxel, 6.8% and 14.2% discontinued because of treatment-related adverse events (TRAEs), respectively; 1.4% and 1.0%, respectively, had TRAEs leading to death. CONCLUSION: Although statistical significance was not met, OS numerically improved with SG versus docetaxel, which was consistent across histologies. Clinically meaningful improvement in OS was noted in mNSCLC nonresponsive to last anti-PD-(L)1-containing regimen. SG was better tolerated than docetaxel and consistent with its known safety profile, with no new safety signals.

2.
Indian J Med Microbiol ; 40(1): 169-171, 2022.
Article in English | MEDLINE | ID: mdl-34238635

ABSTRACT

A young female patient from Ahmedabad city presented with acute febrile illness and bicytopenia (leukopenia and thrombocytopenia). She returned to India after recent visit to East Africa. Human African Trypanosomiasis (Sleeping sickness) was diagnosed by identification of Trypanosoma brucei rhodesiense in peripheral blood smear. She treated successfully with suramin. In India, we account this as second case of HAT after first report before 18 years in the published literature.


Subject(s)
Trypanosomiasis, African , Animals , Female , Fever , Humans , India , Trypanosoma brucei rhodesiense , Trypanosomiasis, African/diagnosis , Trypanosomiasis, African/drug therapy
3.
J Assoc Physicians India ; 64(5): 79-80, 2016 05.
Article in English | MEDLINE | ID: mdl-27735161

ABSTRACT

Phaeohyphomycosis is a term used to describe infections caused by dematiaceous fungi, i.e. fungi which contain melanin in their cell wall. Cladophialophora bantiana has been implicated to cause brain abscess in immunocompromised patients. Infection caused by Cladophialophora bantiana in an immunocompetent host is relatively rare. Surgical site infection at abdominal subcutaneous tissue caused by Cladophialophora bantiana was noted in this case, which was rarely reported.


Subject(s)
Cladosporium/isolation & purification , Phaeohyphomycosis/diagnosis , Wound Infection/microbiology , Antifungal Agents/therapeutic use , Dermatomycoses/drug therapy , Female , Humans , Middle Aged , Mycoses/drug therapy , Opportunistic Infections/microbiology , Phaeohyphomycosis/drug therapy , Phaeohyphomycosis/microbiology , Treatment Outcome , Wound Infection/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...